CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
A study of the recently approved protease inhibitor Reyataz shows that the medication is significantly less likely to boost blood-based lipid levels than similar medications, HIVandHepatitis.com reports. Previous studies have linked protease inhibitors with increases in cholesterol and triglyceride levels, which can put HIV-positive people at a higher risk for cardiac complications. A comparative study of Reyataz and Viracept among treatment-naive subjects showed that while both drugs lowered blood-based HIV viral levels, Reyataz was significantly less likely to boost LDL cholesterol and triglyceride levels. Although the long-term clinical significance of the lipid findings is still unknown, the study authors, writing in the journal AIDS, conclude that Reyataz "is a potent, safe, well-tolerated, and effective once-daily protease inhibitor with low pill burden."
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
A 'Drag Race' queen is leaving the country amid Trump's immigration crackdown
July 17 2025 1:42 AM
Detroit trans woman Karmin Wells shot and killed
July 16 2025 5:53 PM
Daily newsletter 7/16
July 16 2025 5:12 PM
5,000 users leave trans subreddit in wake of transmasculine controversy
July 16 2025 4:10 PM
Cooper Koch’s Emmy nomination earned him a surprise prison call
July 16 2025 3:47 PM
Florida officials claim SCOTUS ruling allows them to deny trans adults health care
July 16 2025 2:43 PM